Craig Morrell is a Professor at the University of Rochester School of Medicine and Dentistry , with joint appointments in the Departments of Medicine , Microbiology and Immunology , and Pathology and Laboratory Medicine . He serves as Associate Director of the Aab Cardiovascular Research Institute . Education: Sc.B. in Biology, Brown University (1995) D.V.M. , Tufts University School of Veterinary Medicine (2000) Ph.D. in Pathobiology, Johns Hopkins University (2005) His research examines the interface between platelets, vascular biology, and immune cells , focusing on platelet roles in thrombosis, inflammation, and immune regulation. Using advanced mouse models , his lab investigates platelet-derived mediators like β2M and PF4 in diseases such as malaria, stroke, and myocardial infarction. Article trends highlight platelets' dual roles in thrombosis and immune modulation , with recurring themes in vascular inflammation , ERK5 signaling , and age-related immune dysfunction . Scientific Awards: Kenneth M. Brinkous Young Investigators Prize (2008) Deans Gift research award (2006) Multiple travel scholarships and fellowships (2003-2005) Pathology Award-Excellence in Pathology (2000) Mentoring and Teaching : He has mentored 8 doctoral students , 7 undergraduates , and 6 postdoctoral fellows , with a focus on diversity. He serves on thesis committees and the URMC MSTP (MD/PhD) admissions committee . Labs and Collaborations : Leads the Morrell Lab at the Aab Cardiovascular Research Institute, collaborating with institutions like Johns Hopkins and Medical College of Wisconsin.
Associate Professor Freda Passam is a Clinical Academic Haematologist at Royal Prince Alfred Hospital, University of Sydney, specializing in thrombosis and haemostasis. She leads the Haematology Research Group at the Charles Perkins Centre, focusing on platelet biology, endothelial cell dysfunction, and translational research in cardiovascular diseases. Her work integrates basic science with clinical applications, including developing microfluidic technologies like the Endo-chip for thrombosis diagnosis and therapy screening. Education: MD and PhD in Greece (angiogenesis in Hodgkin’s lymphoma), postdoctoral training at UNSW and Harvard University. Research spans platelet hyperactivity in diabetes, immune thrombosis (e.g., HIT), and thiol isomerase inhibitors as antithrombotics. Collaborates globally with institutions like Harvard and the University of Utah. Research Interests: 1) Platelet biomarkers in diabetes-related cardiovascular risk; 2) Immune thrombosis diagnostics/therapies (e.g., Endo-chip); 3) Bone marrow-on-chip models for thrombopoiesis. Current projects include SEC61B regulation of calcium flux, endothelial thromboinflammation, and ERp5/ERp57 roles in platelet production. Grants: Over $6M in funding from NHMRC, MRFF, NSW Health, and industry partnerships. Notable awards include Sydney Nano Grand Challenge Award (2022) and SLHD VTE Stewardship Award (2020). Advising: Mentors over 6 PhD/master’s students in thrombosis research, emphasizing clinical/research integration. Teaching includes Sydney Medicine curriculum, bedside tutorials, and student engagement in lab activities. Labs/Teams: Haematology Research Group (Charles Perkins Centre), collaborations with Sydney Health Partners, Harvard, and international haematology groups. Develops technologies like the Endo-chip and bone marrow-on-chip models.
Lorenzo Alberio is a full professor at the University of Lausanne (UNIL), Faculty of Biology and Medicine, and serves as head physician at the Central Hematology Department and Laboratory of the Lausanne University Hospital (CHUV). He has held academic and clinical leadership roles since joining UNIL in 2014 and was promoted to full professor in 2024. His educational background includes a medical degree (1990) and doctorate (1993) from the University of Bern, FMH in internal medicine (1996), and specialist qualifications in hematology (1999) and analytical hematology (2002). He completed research training at the University of Oklahoma (1997–1999). Alberio's research focuses on hemostasis , platelet function , and coagulation disorders . His work includes the development of flow cytometry techniques and assays for procoagulant platelets (COATs), heparin-induced thrombocytopenia, and thrombin generation. His publications span high-impact journals and cover translational and clinical hematology, with a strong emphasis on diagnostic innovation and therapeutic applications. His recent articles reflect a consistent trend in thrombosis , platelet biology , and anticoagulation strategies , often in the context of cancer and critical care. The work bridges basic science with clinical implementation. Scientific awards include: Johann-Lukas-Schönlein Prize (2000) Multiple distinctions from the Swiss Society of Hematology Alberio is deeply committed to education and mentorship, having developed the Lausanne School of Hemostasis and actively teaching at undergraduate and postgraduate levels. He has secured significant research funding from the Swiss National Science Foundation (SNSF) and leads interdisciplinary projects. His research group operates within the Hemostasis & Platelet Research Laboratory at CHUV, part of a broader network including units in blood cancer proteostasis, targeted immunotherapies, and regenerative hematopoiesis. He maintains international collaborations with institutions in Strasbourg, Tübingen, Islamabad, Leuven, Ghent, and Maastricht. He is also President of the GTH Congress (2021, 2025), underscoring his global academic leadership.
Professor John Bjarne Hansen is a prominent researcher in the field of venous thromboembolism (VTE) at the Department of Clinical Medicine, UiT The Arctic University of Norway. He serves as Research Group Leader of Thrombosis Research (TREC) and Head of Unit at the Thrombosis Research Center (TREC), Medical Clinic, University Hospital of Northern Norway. Education: Cand.med (MD), Universitetet i Tromsø (1989) Dr. med (PhD in Cardiovascular Medicine), Universitetet i Tromsø (1997) Hansen's research focuses on clinical epidemiology and risk factors for venous thromboembolism, diagnostic and predictive biomarkers for VTE, and the pathophysiology of thrombotic events. His work spans multiple projects including PREVENT, Mission-VTE, Genetics and VTE, Biomarkers of VTE risk, and Cancer-associated VTE. He has contributed significantly to understanding the complex interplay between genetic factors, lifestyle, and comorbidities in VTE development. His recent publications demonstrate a strong focus on biomarkers for VTE prediction, with numerous 2024-2025 articles examining genetic, molecular, and clinical risk factors. His research utilizes large population studies like the HUNT and Tromsø studies to identify novel predictors and understand gender differences in VTE risk. Hansen has made substantial contributions to thrombosis research through his leadership of the Thrombosis Research Center (TREC) and through active participation in international collaborations. His work bridges basic science and clinical application, with emphasis on translating research findings into improved risk prediction and prevention strategies for venous thromboembolism. Mentorship and Academic Leadership: Primary supervisor for 35 completed PhD theses Co-supervisor for 5 completed PhD theses Currently supervising 7 PhD students as primary supervisor and 6 as co-supervisor Mentored 13 postdoctoral researchers (10 former, 3 current) He has held various academic positions since 1991, progressing from doctoral student to full professor, with a visiting professorship at The Scripps Research Institute (2008-2009). From 2007-2008, he served as Pro-Dean for Research at the Faculty of Health Sciences.
Wolfgang Bergmeier, PhD, is a Professor in the Department of Biochemistry and Biophysics at the University of North Carolina at Chapel Hill. He is a member of the UNC Lineberger Comprehensive Cancer Center and the UNC Blood Research Center, where he leads research on the signaling mechanisms regulating megakaryocyte and platelet function in health and disease. His laboratory employs a multidisciplinary approach including biochemistry, cell and molecular biology, immunology, cutting-edge microscopy, and animal models to investigate platelet biology and its implications for human disease. Dr. Bergmeier's research focuses on understanding small GTPase signaling in platelets, particularly Rap1, and its role in hemostasis, thrombosis, and cancer. His work has made significant contributions to our understanding of how platelets secure vascular integrity, how they contribute to cancer progression and treatment complications, and how platelet function can be optimized for therapeutic purposes. His laboratory has developed novel mouse models and intravital imaging platforms to study platelet function in real-time. Analysis of Dr. Bergmeier's recent publications reveals a strong focus on platelet signaling mechanisms, particularly Rap1 and other small GTPases, and their implications for hemostasis, thrombosis, and cancer. His research spans from fundamental molecular mechanisms to translational applications, including development of novel antithrombotic strategies, optimization of platelet transfusion therapy, and understanding the complex relationship between platelets and cancer progression. Dr. Bergmeier has received numerous awards including the Outstanding Investigator Award from the National Heart, Lung and Blood Institute (NIH) in 2019, the American Heart Association ATVB Special Recognition Award in Thrombosis in 2016, and the Established Investigator Award from the American Heart Association in 2014. He has served as Chair of the 9th Symposium of Hemostasis in Chapel Hill (2018) and Vice Chair of the Gordon Research Conference on the Cell Biology of Platelets and Megakaryocytes (2017). He is also an Associate Editor for the Journal of Thrombosis and Hemostasis. His laboratory actively collaborates with clinical researchers at UNC, particularly with Dr. Nigel Mackman on cancer-related platelet research and with Drs. Flick and Wolberg on the interplay of platelets and the coagulation system. The Bergmeier Lab is part of the UNC BCBP Green Lab initiative, demonstrating a commitment to sustainability in research practices.
Dr. Vivien Chen is an Associate Professor at the Concord Clinical School, University of Sydney, and leader of the Platelet and Thrombosis Research Laboratory at the ANZAC Research Institute. She holds clinical roles as a staff specialist haematologist at Concord Repatriation and General Hospital, leading the thrombosis clinic. Her research focuses on platelet biology, coagulation in cancer, and thrombotic mechanisms in cardiovascular diseases, with a translational emphasis on clinical applications. Education: MBBS (University of Sydney), BA, PhD (University of New South Wales), postdoctoral training at Harvard Medical School. Her expertise bridges basic science and clinical practice, particularly in cancer-associated thrombosis and myeloproliferative disorders. Research Interests: Dr. Chen investigates procoagulant platelet formation pathways, mitochondrial function in platelet activation, and thrombotic complications in conditions like coronary artery disease and sepsis. Her work also explores predictive biomarkers for thrombotic outcomes and novel antithrombotic strategies. Awards: Over 15 prestigious awards, including the Eberhard Mammen Young Investigator Award, NHMRC CJ Martin Fellowship, and University Medal for Medicine. Her recognition spans clinical, research, and educational contributions in thrombosis and haematology. Grants & Collaborations: Leads projects funded by NHMRC, National Heart Foundation, and international networks. Collaborates with institutions in Singapore and the UK on thrombosis mechanisms and clinical trials. Current studies include platelet-targeted therapies for coronary artery disease and biomarker discovery in myeloproliferative neoplasms. Labs & Teams: Directs the Platelet and Thrombosis Research Laboratory, integrating vascular biology and clinical haematology research. Engages in interdisciplinary projects with the Sydney Platelet Group and ANZAC Research Institute.
Professor Valerie O'Donnell is a distinguished academic at Cardiff University's School of Medicine, where she serves as Professor of Biochemistry and Co-Director of the Systems Immunity Research Institute (SIURI), established in 2016 with £4.5M funding. She leads the internationally recognized LIPID MAPS project (www.lipidmaps.org) and Cardiff Lipidomic Facility, positioning her at the forefront of lipidomics research. With over two decades of academic leadership, she previously served as Director of the Division of Infection and Immunity (2017-2020) and Dean of Research for the School of Medicine (2012-2014). Professor O'Donnell earned her Ph.D. in Biochemistry from the University of Bristol (1990-1993) working with Prof. OTG Jones and Dr. PJ England of SmithKline Beecham Pharmaceuticals, following her B.Sc. in Human Nutrition & Dietetics (Hons. 2.1) from University of Dublin, Trinity College, Ireland (1985-1989). Her academic journey includes prestigious fellowships at the University of Alabama at Birmingham and University of Bern, Switzerland, before establishing her career at Cardiff University. Her research focuses on using mass spectrometry to discover and characterize bioactive lipids made by circulating vascular cells that regulate immune defense and blood clotting. Over the past 20 years, her lab discovered large families of enzymatically-oxidized phospholipids (eoxPL) and has worked extensively on their structures, signaling actions in thrombosis and innate immunity. Current research examines the role of bioactive lipids in vascular inflammation including abdominal aortic aneurysm, cardiovascular disease, dementia and wound healing. Analysis of her recent publications reveals a strong emphasis on lipidomics methodology development, clinical applications of lipid research, and the role of specific lipids in disease mechanisms. Her work spans analytical chemistry, cardiovascular biology, immunology, and clinical translation, with particular focus on procoagulant lipids, oxylipins, and specialized pro-resolving mediators. The research demonstrates increasing interdisciplinary collaboration and methodological standardization efforts in the lipidomics field. Professor O'Donnell's scientific achievements have been recognized with numerous prestigious awards: 2023: Honorary Officer of the Order of the British Empire (OBE) for services to biochemical research 2020: Fellow of the Academy of Medical Sciences 2019: Journal of Lipid Research Lectureship Award 2016: Wolfson Research Merit Award, Royal Society 2015: Fellow of the Learned Society of Wales 2013: Fellow of the Royal Society of Biology She currently serves as Principal Investigator for British Heart Foundation and Wellcome Trust funding, while also participating as co-Investigator for Medical Research Council (MRC), EU (Marie Curie ITN), and Welsh Government projects. Her panel memberships include Population Systems Medicine Board (MRC) and Biomedical Resources Committee (Wellcome Trust). With a Google Scholar H-index of 52, she has been included in UK national research assessments RAE2002, RAE2008, and REF2014. Professor O'Donnell leads the Systems Immunity Research Institute, a strategic research institute at Cardiff University, and directs the Cardiff Lipidomic Facility as part of the LIPID MAPS consortium. Her laboratory continues to make significant contributions to understanding how bioactive lipids regulate vascular inflammation and coagulation, with recent work focusing on the role of specific phospholipids in conditions ranging from cardiovascular disease to SARS-CoV-2 infection. In 2024, LIPID MAPS became an ELIXIR Core Data Resource and a member of the Global Biodata Coalition, with an MRC Partnership Grant commencing funding.
Dr Cédric Duval is a Lecturer and BHF Intermediate Fellow within the School of Medicine at the University of Leeds , affiliated with the Discovery and Translational Science Department and LICAMM laboratories. His research focuses on molecular mechanisms of thromboinflammation and blood clotting. BSc in Physiology and Molecular Biology (University of Rennes, France) MRes in Cellular Biology and Physiology (University of Nice, France) PhD in Cellular and Molecular Physiology (University of Liverpool) Research Interests : Investigating the roles of Factor XIII and fibrinogen in inflammation-driven thrombosis, platelet hyperactivation, and neutrophil extracellular traps (NETs) in thromboembolism. Developing in-vivo models for thromboinflammation and studying clot formation mechanics. Article Trends : Recent publications emphasize clot ultrastructure analysis , GPVI interactions , inflammatory mediators in thrombosis, and novel murine models for studying Factor XIII variants. Research highlights clinical implications for thrombolysis and autoimmune disease. Scientific Awards : BHF Intermediate Basic Science Research Fellowship (2023) Associate Fellow of the Higher Education Academy Advising & Grants : Supervised 6 PhD students and 6 intercalated BSc students. Secured over £3 million in grants including BHF Accelerator Award (£1M, 2024-2029), BHF Programme Grant (£1.3M, 2024-2028), and multiple MRC and institutional scholarships. Labs & Collaborations : Leads research within LICAMM and collaborates with University of Massachusetts – Lowell on computational modeling. Affiliated with BHF Cardiovascular Research and Multidisciplinary Cardiovascular Research Centre .
Dr Josh Bourne is a Postdoctoral Research Fellow at Monash University's Centre for Inflammatory Disease (part of Monash Health Victorian Heart Institute). His research focuses on neuroinflammation following ischaemic stroke, investigating the interplay between thrombosis, coagulation factors, and inflammation. He completed his PhD at the University of Birmingham (UK), studying platelet receptor CLEC-2 in thrombosis and inflammation, resulting in six first-author publications. Relocating to Melbourne, he trained in intravital microscopy under Associate Professor Connie Wong. Education: PhD in Cardiovascular Science (University of Birmingham, 2022), MSc in Oncology (University of Nottingham, 2018), BSc in Medical Physiology and Therapeutics (University of Nottingham, 2016). Research Interests: Innate Immunity, Thrombosis, Thromboinflammation, Stroke, Platelet Biology, Macrophage Polarisation, Microglia. Awards: AVBS ECR Rising Star (2023), BSI Bright Spark in Immunology (2021), ECR Award (2024), FMNHS Postdoctoral Fellowship (2024). Secured over $350,000 in competitive grants. Projects: Leads 'TISN: Tackling Ischaemic Stroke with Nanomedicine' and collaborates on 'Delivery of pH-responsive nanoparticles to reduce thrombo-inflammation'. Labs/Teams: Monash Neuroinflammation Group, collaborating with global experts in thrombosis and intravital imaging.
Dr Camille Ettelaie is a Lecturer in Biomedical Science, with a research focus on the role of tissue factor in coagulation, cancer progression, and cellular signaling pathways. Her work spans molecular mechanisms, extracellular vesicles, and translational applications in thrombosis and cancer diagnostics. Research Interests : Dr Ettelaie investigates tissue factor biology, including its regulation via phosphorylation, ubiquitination, and interactions with integrins and protease-activated receptors (PAR2). Her studies explore the non-haemostatic roles of coagulation proteases in cancer, endothelial dysfunction, and vascular inflammation. Key Trends in Recent Publications : Recent articles address extracellular vesicle heterogeneity, MISEV2023 guidelines for EV research, tissue factor's role in pancreatic cancer diagnostics, and cross-talk between coagulation and inflammation. Earlier work includes studies on geomechanics, calcitonin receptor networks, and lipid metabolism in coagulation.
Professor Valerie O'Donnell is a leading academic in lipid biochemistry at Cardiff University's School of Medicine, specializing in the Division of Infection and Immunity. Her research focuses on lipid signaling in thrombosis, innate immunity, and vascular diseases using mass spectrometry. Key areas include enzymatically oxidized phospholipids (eoxPL) and their roles in blood clotting, inflammation, and conditions like atherosclerosis and dementia. She leads the LIPID MAPS initiative, a global lipidomics resource, and her work has advanced understanding of lipid mediators in viral envelopes (e.g., SARS-CoV-2) and aspirin's effects. Awards include FLSW, FMedSci, and an OBE. Research Interests: Procoagulant lipids, oxylipin metabolism, lipidomics standardization, and cardiovascular disease mechanisms. Grants: MRC Partnership Grant (2024), British Heart Foundation Program Grant. Labs/Teams: O'Donnell Lab (Cardiff), collaborating with institutions like Babraham Institute and University of Cambridge. Her >250 publications include seminal work on lipid biomarkers and their clinical applications, with recent focus on aging-related inflammation and viral pathogenesis.
Anirban Sen Gupta is the Wallace R. Persons Professor in the Department of Biomedical Engineering at Case School of Engineering and a member of the Cancer Imaging Program at Case Comprehensive Cancer Center. His research focuses on drug delivery and nanomedicine, particularly targeting hemostasis, thrombosis, inflammation, and cancer metastasis. Key projects include developing platelet-mimicking nanoparticles for trauma hemostasis and neutrophil-targeted nanomedicines using α1-antitrypsin-derived peptides. Research interests span biomaterials engineering, disease-targeted drug delivery systems, and understanding pathophysiological mechanisms of cardiovascular diseases. His lab integrates biochemical and biophysical tools (e.g., ligand-receptor interactions, nanoparticle morphology) to create customizable therapies. Recent work includes injury-targeted thrombin delivery, anti-inflammatory nanomedicines, and synthetic platelet surrogates for battlefield hemorrhage control. Notable publications (2022–2025) highlight advancements in nanotechnology-based hemostatic agents, thrombolytic therapies, and tumor microenvironment modulation. His work bridges engineering and medicine, addressing clinical challenges in trauma care, oncology, and chronic inflammation.
A. Koneti Rao, MD is a Professor in the Department of Pathology and Laboratory Medicine at Thomas Jefferson University's Lewis Katz School of Medicine. He serves as Co-Director and holds the Sol Sherry Professorship at the Sol Sherry Thrombosis Research Center. His work bridges clinical and molecular hemostasis research. MBBS, All India Institute of Medical Sciences (1973) Internship, Albert Einstein Medical Center (1975) Residency, Thomas Jefferson University Hospital (1977) Fellowships in Hematology/Oncology (Temple University) and Hematology (Cardeza Foundation). Rao's research focuses on molecular mechanisms in inherited platelet disorders , particularly the role of RUNX1 transcription factor in regulating genes like MYL9, ALOX12, PF4, and PRKCQ. His work connects platelet dysfunction to cardiovascular events and explores hyperglycemia/hyperinsulinemia's impact on tissue factor pathways in diabetes. Current studies aim to identify novel antiplatelet targets and understand thrombosis in metabolic disorders. His article trends reveal RUNX1 as a central regulator of platelet gene expression, with implications for clot stability, endosomal trafficking, and cardiovascular risk. Collaborative studies with Dr. Guenther Boden highlight diabetes' procoagulant effects. Institute Prize for Distinction in Pharmacology Rao has received NIH and March of Dimes funding. His team at the Sol Sherry Thrombosis Research Center investigates transcriptional regulation of platelet proteins and coagulation activation in metabolic and hematological diseases.
Dr. Caroline Reddel is an Adjunct Lecturer in Medical Sciences and a Research Fellow at the ANZAC Research Institute, affiliated with the Concord Clinical School at the University of Sydney's Faculty of Medicine and Health. She specializes in vascular biology and thrombosis research, focusing on platelet activation, coagulation assays, and hypercoagulable conditions in clinical populations such as coronary artery disease, cancer, and schizophrenia. Education: Completed her PhD in 2009 at the University of Sydney under Prof. Tony Weiss in the School of Molecular Bioscience. Postdoctoral research at ANZAC Research Institute. Research Interests : Thrombosis mechanisms, platelet-derived microparticles, global coagulation assays, risk stratification in cardiovascular and oncological diseases, and anticoagulant efficacy. Her work integrates clinical and preclinical models, including mouse studies of cancer cachexia. Publications : Over 15 peer-reviewed articles since 2004, with recent focus on colchicine's anti-thrombotic effects, platelet phenotypes in the elderly, and hypercoagulability in schizophrenia patients. Key themes include translational research bridging basic science and clinical applications. Grants : Co-investigator on the 2020 Apixaban vs. Rivaroxaban trial (MRFF-funded). Labs/Teams : Vascular Biology Group at ANZAC Research Institute, collaborating with Cardiology and Haematology departments at Concord Hospital.
Marvin T. Nieman is a Professor in the Department of Pharmacology at Case Western Reserve University School of Medicine. He also serves as Vice Provost and Dean for Graduate Studies, providing strategic leadership to enhance graduate student success in research and teaching. Additionally, he is a member of the Molecular Oncology Program at the Case Comprehensive Cancer Center, reflecting his interdisciplinary research interests. Dr. Nieman holds a PhD in Cell Biology from the University of Toledo and a Bachelor of Science in Biochemistry from Eastern Michigan University. His research focuses on platelet signaling mechanisms, particularly the role of protease-activated receptors (PARs) in thrombosis and cancer. He explores how PARs interact with other GPCRs to mediate protease signaling, using structural biology, cell signaling analyses, and animal models. Key areas include PAR4's role in stable clot formation, PAR heterodimerization effects on thrombin signaling, and platelet interactions with immune cells like neutrophils and tumor cells. His work highlights the importance of PAR4 in antiplatelet therapy and its genetic variants influencing disease outcomes. He has been recognized for his contributions with awards such as the Sol Sherry Distinguished Lecture (2022), FAHA (2018), and AACR-AFLAC Scholar (1999). He also engages in educational leadership, having co-founded the CWRU chapter of the Society for Advancing Chicanos/Hispanics and Native Americans in Science (SACNAS). Dr. Nieman’s advising and grants focus on graduate student mentorship and collaborative projects in hemostasis and thrombosis. His lab contributes to understanding molecular mechanisms of platelet function and their implications in diseases like cancer and cardiovascular disorders. He actively participates in professional societies including the American Heart Association and American Society for Hematology.
